This weekly update in vaccine research covers clinical data releases, infectious disease strategy expansion, manufacturing partnerships, and platform development advances across oncology, neurology, and emerging infectious diseases.
In Today’s Newsletter
Dive deeper
💉 Personalized mRNA melanoma vaccine shows long-term follow-up benefit [1] [US • 01 Jun 2026]
https://www.dongascience.com/en/news/78023
Context: The randomized analysis included 107 patients in the combination arm and 50 patients receiving pembrolizumab monotherapy. Recurrence-free survival and distant metastasis outcomes favored the combination regimen.
Key point: NYU Langone Health reported five-year follow-up data showing intismeran plus pembrolizumab reduced recurrence or death risk versus pembrolizumab alone after melanoma surgery.
Implication: May influence prescriber choice and payer reviews pending full data.
🧠 Alzinova prepares Phase II path for Alzheimer’s vaccine ALZ-101 [2] [EU • 28 May 2026]
https://biostock.se/en/2026/05/kliniska-framsteg-banar-vag-mot-alzinovas-fas-ii/
Context: The company reported no ARIA events in Phase Ib and described exploratory biomarker and cognitive signals (study small; efficacy not established). FDA Fast Track and IND clearance were previously obtained.
Key point: Alzinova said operational preparations for a global Phase II study of ALZ-101 are advancing following Phase Ib safety and immunogenicity findings.
Implication: Signals pipeline investment and modality expansion.
🦠 Lilly expands infectious disease strategy with three acquisitions [3] [US • 26 May 2026]
https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease
Context: Assets include a shingles vaccine candidate (amezosvatein), bacterial vaccine programs targeting antimicrobial resistance, and nanoparticle vaccine technology focused initially on Epstein-Barr virus.
Key point: Eli Lilly agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company to strengthen vaccine and infectious disease R&D capabilities.
Implication: Signals pipeline investment and modality expansion.
🌍 Soligenix highlights thermostable Bundibugyo virus vaccine platform [4] [US • 26 May 2026]
https://ir.soligenix.com/2026-05-26-Suitability-of-Vaccine-Platform-for-Bundibugyo-Virus,-Cause-of-the-Ebola-Outbreak-in-Congo
Context: Prior work demonstrated thermostability and protective efficacy against related Ebola-family viruses in preclinical models, including non-human primates.
Key point: Soligenix stated its ThermoVax® filovirus platform may provide a rapid starting point for Bundibugyo virus vaccine development amid the Congo outbreak.
Implication: May expand screening, initiation, and follow-up at scale.
🧬 GeoVax prioritizes mpox vaccine and oncology programs [5] [US • 26 May 2026]
https://www.geovax.com/investors/press-releases/geovax-accelerates-focus-on-geo-mva-commercialization-and-advancement-of-oncology-program-gedeptin-r
Context: GEO-MVA is advancing through an EMA-supported immunobridging pathway for mpox/smallpox, while Gedeptin is being positioned for combination use with pembrolizumab in head and neck cancer.
Key point: GeoVax discontinued active development of its GEO-CM04S1 COVID-19 vaccine candidate to prioritize GEO-MVA and Gedeptin®.
Implication: Signals pipeline investment and modality expansion.
🏭 Intravacc secures French CIR approval for vaccine R&D partnerships [6] [EU • 27 May 2026]
https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/intravacc-secures-french-cir-approval-to-support-vaccine-rd-partnerships/2352556/amp
Context: The company supports viral, bacterial, conjugate, and protein-based vaccine programs with analytical development and cGMP manufacturing services.
Key point: Intravacc received French CIR approval covering 2025–2027, enabling eligible French partners to include outsourced R&D activities under the tax credit framework.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
🌎 SK bioscience and Colombia’s VECOL launch vaccine manufacturing partnership [7] [LATAM • 28 May 2026]
https://www.skbioscience.com/en/news/news_01_01?mode=view&id=352
Context: SKYVaricella was selected as the initial vaccine for local manufacturing, with broader portfolio expansion under consideration. Colombia’s initiative includes approximately US$260 million in planned investment over 10 years.
Key point: SK bioscience signed a technology transfer and manufacturing agreement with Colombia’s VECOL as part of a national vaccine localization initiative.
Implication: May expand screening, initiation, and follow-up at scale.
Why it matters
- Personalized cancer vaccines continue to generate longer-term melanoma data, supporting broader interest in neoantigen-directed immunotherapy combinations. [1]
- Alzheimer’s vaccine developers are revisiting active immunotherapy approaches with greater emphasis on safety, precision targeting, and outpatient administration. [2]
- Large pharmaceutical companies are increasing investment in infectious disease prevention platforms, including bacterial vaccines and EBV-directed technologies. [3]
- Thermostable vaccine formulations may improve outbreak response logistics in regions with limited cold-chain infrastructure. [4]
- Regional manufacturing and technology transfer initiatives are becoming central to vaccine supply resilience strategies across LATAM and other emerging markets. [7]
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Vaccine news from the past two weeks, curated by the LucidQuest team.
FAQ
What is intismeran in melanoma treatment? [1]
Intismeran is a personalized mRNA cancer vaccine designed using neoantigens identified from an individual patient’s melanoma tumor. In the reported study, it was combined with pembrolizumab after surgery to reduce recurrence risk. [1]
What differentiates Alzinova’s ALZ-101 from approved Alzheimer’s antibodies? [2]
ALZ-101 is an active immunotherapy vaccine intended to stimulate endogenous antibody production against oligomeric amyloid-beta forms. Alzinova also emphasized outpatient-style administration and reported no ARIA events in Phase Ib. [2]
Which vaccine assets is Lilly acquiring? [3]
Lilly’s announced transactions include Curevo’s shingles vaccine candidate amezosvatein, LimmaTech’s bacterial vaccine platform, and Vaccine Company’s nanoparticle vaccine technologies focused initially on EBV. [3]
Why is thermostability important for filovirus vaccines? [4]
Soligenix said thermostable formulations may simplify storage and distribution in outbreak-prone regions by reducing dependence on ultra-cold supply chains. The company reported stability data for at least two years at elevated temperatures. [4]
What is GEO-MVA designed to target? [5]
GeoVax’s GEO-MVA is an MVA-based vaccine candidate targeting mpox and smallpox. The company said it is pursuing an expedited regulatory pathway supported by EMA scientific advice. [5]
What is the significance of the SK bioscience–VECOL agreement? [7]
The partnership supports Colombia’s vaccine localization strategy through technology transfer and local manufacturing capabilities, beginning with SKYVaricella production. [7]
Entities / Keywords
Intismeran (personalized mRNA melanoma vaccine), Pembrolizumab (Keytruda), NYU Langone Health, Moderna, Merck, ALZ-101, Alzinova, Alzheimer’s disease vaccine, Eli Lilly and Company, Curevo, Amezosvatein, LimmaTech Biologics, Vaccine Company, Epstein-Barr virus (EBV), Soligenix, ThermoVax, Bundibugyo virus, Filovirus vaccines, GeoVax, GEO-MVA, Gedeptin, Intravacc, Crédit d’Impôt Recherche (CIR), SK bioscience, VECOL, SKYVaricella, Vaccine localization
